Financials data is unavailable for this security.
View more
Year on year Integra Lifesciences Holdings Corp 's net income fell 7,337.70% from a loss of 6.94m to a larger loss of 516.47m despite flat revenues. A contributing factor has been an increase in the percentage of sales devoted to the cost of goods sold from 40.73% to 43.38%.
| Gross margin | 56.62% |
|---|---|
| Net profit margin | -31.58% |
| Operating margin | -30.20% |
| Return on assets | -13.52% |
|---|---|
| Return on equity | -39.90% |
| Return on investment | -16.50% |
More ▼
Cash flow in USDView more
In 2025, Integra Lifesciences Holdings Corp did not generate a significant amount of cash. However, the company earned 50.38m from its operations for a Cash Flow Margin of 3.08%. In addition the company generated 28.34m cash from financing while 108.06m was spent on investing.
| Cash flow per share | -4.76 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 13.40 |
|---|---|
| Tangible book value per share | -9.07 |
More ▼
Balance sheet in USDView more
| Current ratio | 2.54 |
|---|---|
| Quick ratio | 1.46 |
| Total debt/total equity | 1.78 |
|---|---|
| Total debt/total capital | 0.6401 |
More ▼
Growth rates in USD
SmartText is unavailable
| EPS growth(5 years) | -- |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -7,543.91 |
